These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20555034)

  • 1. Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia.
    Zenzmaier C; Sampson N; Pernkopf D; Plas E; Untergasser G; Berger P
    Endocrinology; 2010 Aug; 151(8):3975-84. PubMed ID: 20555034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase type 5 inhibition reverts prostate fibroblast-to-myofibroblast trans-differentiation.
    Zenzmaier C; Kern J; Sampson N; Heitz M; Plas E; Untergasser G; Berger P
    Endocrinology; 2012 Nov; 153(11):5546-55. PubMed ID: 22948216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS.
    Vignozzi L; Gacci M; Cellai I; Morelli A; Maneschi E; Comeglio P; Santi R; Filippi S; Sebastianelli A; Nesi G; Serni S; Carini M; Maggi M
    Prostate; 2013 Sep; 73(13):1391-402. PubMed ID: 23765639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase type 5 inhibitor tadalafil reduces prostatic fibrosis via MiR-3126-3p/FGF9 axis in benign prostatic hyperplasia.
    Li T; Zhang Y; Zhou Z; Guan L; Zhang Y; Zhou Z; Wang W; Zhou X; Cui D; Jiang C; Ruan Y
    Biol Direct; 2024 Aug; 19(1):61. PubMed ID: 39095835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of cGMP/PKG/p65 signaling associated with PDE5-Is downregulates CCL5 secretion by CD8
    Jin S; Xiang P; Liu J; Yang Y; Hu S; Sheng J; He Q; Yu W; Han W; Jin J; Peng J
    Prostate; 2019 Jun; 79(8):909-919. PubMed ID: 30958912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dickkopf-related protein 3 promotes pathogenic stromal remodeling in benign prostatic hyperplasia and prostate cancer.
    Zenzmaier C; Sampson N; Plas E; Berger P
    Prostate; 2013 Sep; 73(13):1441-52. PubMed ID: 23765731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [PDE5 inhibitors in treatment of benign prostatic syndrome].
    Sandner P; Tinel H; Stelte-Ludwig B; Huetter J; Neuser D; Bischoff E; Ulbrich E
    Urologe A; 2007 Sep; 46(9):1189-92. PubMed ID: 17609921
    [No Abstract]   [Full Text] [Related]  

  • 8. Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit.
    Morelli A; Comeglio P; Filippi S; Sarchielli E; Vignozzi L; Maneschi E; Cellai I; Gacci M; Lenzi A; Vannelli GB; Maggi M
    Prostate; 2013 Mar; 73(4):428-41. PubMed ID: 22996758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
    Gonzalez RR; Kaplan SA
    Expert Opin Drug Metab Toxicol; 2006 Aug; 2(4):609-17. PubMed ID: 16859408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Medicinal therapy of benign prostate syndrome with phosphodiesterase-5 inhibitors].
    Herlemann A; Gratzke C; Andersson KE; Sievert KD
    Urologe A; 2013 Feb; 52(2):204-11. PubMed ID: 23417046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
    Tinel H; Stelte-Ludwig B; Hütter J; Sandner P
    BJU Int; 2006 Dec; 98(6):1259-63. PubMed ID: 16956354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract.
    Fibbi B; Morelli A; Vignozzi L; Filippi S; Chavalmane A; De Vita G; Marini M; Gacci M; Vannelli GB; Sandner P; Maggi M
    J Sex Med; 2010 Jan; 7(1 Pt 1):59-69. PubMed ID: 19796053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tadalafil for the treatment of benign prostatic hyperplasia.
    Mónica FZ; De Nucci G
    Expert Opin Pharmacother; 2019 Jun; 20(8):929-937. PubMed ID: 30901259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells.
    Zenzmaier C; Kern J; Heitz M; Plas E; Zwerschke W; Mattesich M; Sandner P; Berger P
    Exp Cell Res; 2015 Nov; 338(2):162-9. PubMed ID: 26410556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase 5/protein kinase G signal governs stemness of prostate cancer stem cells through Hippo pathway.
    Liu N; Mei L; Fan X; Tang C; Ji X; Hu X; Shi W; Qian Y; Hussain M; Wu J; Wang C; Lin S; Wu X
    Cancer Lett; 2016 Aug; 378(1):38-50. PubMed ID: 27179930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue.
    Uckert S; Sormes M; Kedia G; Scheller F; Knapp WH; Jonas U; Stief CG
    Urology; 2008 Mar; 71(3):526-30. PubMed ID: 18342202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms--action of two new agents.
    Kumar R; Verma V; Sarswat A; Maikhuri JP; Jain A; Jain RK; Sharma VL; Dalela D; Gupta G
    Invest New Drugs; 2012 Apr; 30(2):582-93. PubMed ID: 21181231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of the cGMP/PKG/ERK signaling pathway associated with PDE5Is inhibits fibroblast activation by downregulating autophagy in early progressive benign prostatic hyperplasia.
    Jin S; Liu Z; Xiang P; Fu M; Zhang G; Li J; Niu Y
    World J Urol; 2024 May; 42(1):333. PubMed ID: 38761255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neck.
    Angulo J; Cuevas P; Fernández A; La Fuente JM; Allona A; Moncada I; Sáenz de Tejada I
    J Sex Med; 2012 Sep; 9(9):2293-306. PubMed ID: 22759598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats.
    Morelli A; Sarchielli E; Comeglio P; Filippi S; Mancina R; Gacci M; Vignozzi L; Carini M; Vannelli GB; Maggi M
    J Sex Med; 2011 Oct; 8(10):2746-60. PubMed ID: 21812935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.